Reprogrammed Interchange Llc Sells 350,000 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 350,000 shares at an average price of $1.82, totaling approximately $637,000, which decreased their ownership by 1.01%.
• Vor Biopharma's stock price decreased to $1.80 following multiple sales by the insider, with a market cap of $228.03 million and an average target price of $6.07 according to analysts.
• Institutional investors continue to show interest in Vor Biopharma, with 97.29% of the stock currently owned by institutional investors and hedge funds.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 350,000 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $1.82, for a total value of $637,000.00. Following the completion of the transaction, the insider owned 34,213,292 shares of the company's stock, valued at $62,268,191.44. The trade was a 1.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total value of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.97, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total value of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total transaction of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total transaction of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,229,410.47.
• On Tuesday, August 26th, Reprogrammed Interchange Llc sold 284,190 shares of Vor Biopharma stock. The stock was sold at an average price of $2.08, for a total transaction of $591,115.20.
• On Monday, August 25th, Reprogrammed Interchange Llc sold 387,346 shares of Vor Biopharma stock. The stock was sold at an average price of $2.12, for a total transaction of $821,173.52.

Vor Biopharma Price Performance

NYSE VOR traded down $0.21 on Wednesday, reaching $1.80. The company had a trading volume of 6,041,745 shares, compared to its average volume of 7,646,274. The firm has a market cap of $228.03 million, a price-to-earnings ratio of -1.09 and a beta of 2.05. Vor Biopharma Inc. has a fifty-two week low of $0.13 and a fifty-two week high of $3.29. The business has a 50 day moving average of $2.11 and a two-hundred day moving average of $1.12.

Analysts Set New Price Targets

A number of research firms recently commented on VOR. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Vor Biopharma has an average rating of "Moderate Buy" and an average target price of $6.07.

Institutional Investors Weigh In On Vor Biopharma

Large investors have recently bought and sold shares of the stock. Two Sigma Investments LP raised its holdings in shares of Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares during the period. Money Concepts Capital Corp grew its stake in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the period. XTX Topco Ltd bought a new stake in Vor Biopharma in the 2nd quarter valued at about $66,000. Northern Trust Corp increased its position in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after buying an additional 44,252 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares during the period. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.